In April 2017, the FDA (U.S. Food and Drug Administration) approved Neurocrine Biosciences’ (NBIX) Ingrezza (valbenazine) as the first drug for the treatment of tardive dyskinesia. Tardive dyskinesia is a neural disorder characterized by repetitive involuntary movements of the jaw, lips, and tongue.
In KINECT, a Phase 3 trial, the drug demonstrated promising results. The trial was conducted to evaluate the safety and efficacy of valbenazine in individuals with schizophrenia, schizoaffective disorder, or moderate to severe tardive dyskinesia (or TD). In the trial, Ingrezza (valbenazine) demonstrated a significant response compared to a placebo. Around 30.0% of patients witnessed TD reduction with Ingrezza 80 mg (milligrams). The primary endpoint of the study was a mean change from the baseline in the Abnormal Involuntary Movement Scale (or AIMS) dyskinesia total score compared to a placebo.
Neurocrine Biosciences entered into a collaboration with AbbVie (ABBV) in June 2010 for the development and commercialization of elagolix. The two companies will also develop and commercialize the next-generation GnRH (gonadotropin-releasing hormone).
In March 2015, Neurocrine Biosciences and Mitsubishi Tanabe Pharma entered into a collaboration and agreement for the development and commercialization of NBI-98854 in selected regions. NBI-98854 is a drug in clinical trials for the treatment of TD and chorea-associated Huntington’s disease.
In February 2017, Neurocrine Biosciences entered into an agreement with Bial for the development and commercialization of opicapone in the United States and Canada.
These collaborations may help these companies launch new drugs and build stronger product portfolios. Revenue growth for Neurocrine Biosciences could boost the stock of the First Trust NYSE Arca Biotechnology ETF (FBT). The company accounts for about 2.7% of FBT’s total portfolio holdings.
Thirteen analysts were analyzing Neurocrine Biosciences in June 2017. Five of them have recommended a “strong buy,” and eight have recommended a “buy.” No analysts have recommended a “hold,” “sell,” or “strong sell.” All of them have recommended some form of “buy.”
Twenty-eight analysts were analyzing Celgene (CELG) in June 2017. Around ~82.0% of them have recommended some form of “buy,” while one analyst has recommended a “sell.” Four analysts recommended a “hold.”
Of the 21 analysts analyzing AbbVie (ABBV) in June 2017, 12 of them have recommended a “hold.” None of them have recommended a “sell” or “strong sell.”
Of the 23 analysts analyzing Bristol-Myers Squibb (BMY) in June 2017, ten have recommended a “hold.” Around 43.0% have recommended some form of “buy.” Three have recommended a “sell,” while none of them have recommended a “strong sell.”